OBJECTIVE: To explore fear of recurrence (FoR) in long-term testicular cancer survivors (TCSs) since FoR hardly has been examined in TCSs. METHODS: In a cross-sectional questionnaire study, 1336 TCSs at a mean of 11.4 years (SD 4.2) after diagnosis gave information about their medical and social situation, and completed measures on mental distress, fatigue, quality of life, coping, self-esteem and neuroticism. FoR during the last week was explored with one question, with the response categories rated on a 4-point Likert scale. Nine percent of the TCSs had a structured psychiatric interview. RESULTS: Twenty-four percent of the TCSs reported 'quite a bit' FoR and 7% reported 'very much' FoR during the last week. The FoR question showed moderate correlations (0.22-0.51) with established psychological measures. The level of FoR was significantly positively correlated with mental distress, fatigue and neuroticism and significantly negatively correlated with quality of life, self-esteem and coping. In univariate analyses, neurotoxic side effects and somatic symptoms, but not treatment modality, were significantly associated with level of FoR. In a multivariate analysis, a medium educational level, increasing levels of traumatic cancer-related stress symptoms and of neuroticism were significantly associated with rising FoR. Among those who had a psychiatric interview, the presence of at least one current mental disorder was significantly associated with FoR. CONCLUSIONS: High levels of FoR in long-term TCSs are not uncommon. Levels of mental and somatic problems are associated with the levels of FoR. Clinical consequences of these findings for TCSs are discussed.
OBJECTIVE: To explore fear of recurrence (FoR) in long-term testicular cancer survivors (TCSs) since FoR hardly has been examined in TCSs. METHODS: In a cross-sectional questionnaire study, 1336 TCSs at a mean of 11.4 years (SD 4.2) after diagnosis gave information about their medical and social situation, and completed measures on mental distress, fatigue, quality of life, coping, self-esteem and neuroticism. FoR during the last week was explored with one question, with the response categories rated on a 4-point Likert scale. Nine percent of the TCSs had a structured psychiatric interview. RESULTS: Twenty-four percent of the TCSs reported 'quite a bit' FoR and 7% reported 'very much' FoR during the last week. The FoR question showed moderate correlations (0.22-0.51) with established psychological measures. The level of FoR was significantly positively correlated with mental distress, fatigue and neuroticism and significantly negatively correlated with quality of life, self-esteem and coping. In univariate analyses, neurotoxic side effects and somatic symptoms, but not treatment modality, were significantly associated with level of FoR. In a multivariate analysis, a medium educational level, increasing levels of traumatic cancer-related stress symptoms and of neuroticism were significantly associated with rising FoR. Among those who had a psychiatric interview, the presence of at least one current mental disorder was significantly associated with FoR. CONCLUSIONS: High levels of FoR in long-term TCSs are not uncommon. Levels of mental and somatic problems are associated with the levels of FoR. Clinical consequences of these findings for TCSs are discussed.
Authors: Christian Falk Dahl; Hege Sagstuen Haugnes; Roy Bremnes; Olav Dahl; Sophie D Fosså; Olbjørn Klepp; Erik Wist; Alv A Dahl Journal: J Cancer Surviv Date: 2010-06-24 Impact factor: 4.442
Authors: Allan Ben Smith; Phyllis Butow; Ian Olver; Tim Luckett; Peter Grimison; Guy C Toner; Martin R Stockler; Elizabeth Hovey; John Stubbs; Sandra Turner; George Hruby; Howard Gurney; Mahmood Alam; Keith Cox; Madeleine T King Journal: J Cancer Surviv Date: 2015-07-16 Impact factor: 4.442
Authors: Kelly Yu-Hsin Liao; Nelson C Y Yeung; Celia C Y Wong; Krystal Warmoth; Qian Lu Journal: Support Care Cancer Date: 2016-12-06 Impact factor: 3.603
Authors: Sophie Elisabeth Groß; Anika Nitzsche; Tristan D Gloede; Lena Ansmann; Richard Street; Holger Pfaff; Melanie Neumann; Markus Wirtz; Walter Baumann; Stephan Schmitz; Nicole Ernstmann Journal: Support Care Cancer Date: 2014-09-25 Impact factor: 3.603
Authors: Jacqueline L Bender; David Wiljer; Matthew J To; Philippe L Bedard; Peter Chung; Michael A S Jewett; Andrew Matthew; Malcolm Moore; Padraig Warde; Mary Gospodarowicz Journal: Support Care Cancer Date: 2012-03-03 Impact factor: 3.603
Authors: Daniel L Hall; Rachel B Jimenez; Giselle K Perez; Julia Rabin; Katharine Quain; Gloria Y Yeh; Elyse R Park; Jeffrey M Peppercorn Journal: J Oncol Pract Date: 2019-07-12 Impact factor: 3.840
Authors: Andrea A Cohee; Rebecca N Adams; Shelley A Johns; Diane Von Ah; Kathleen Zoppi; Betsy Fife; Patrick O Monahan; Timothy Stump; David Cella; Victoria L Champion Journal: Psychooncology Date: 2015-10-21 Impact factor: 3.894